Project development in the food and pharmaceutical manufacturing equipment sector
First written in FY2017-Q1. 18 of 27 entries say "Advanced", first in FY2017. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In addition, in the metals and advanced materials and life sciences fields, the company is carrying out multiple EPC projects in Japan.」
The company states that it is carrying out multiple EPC projects in Japan in the life sciences field. - FY2025AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company is carrying out EPC work for pharmaceutical manufacturing facilities for multiple customers, including AGC㈱. It completed an FS for biopharmaceuticals and newly secured an order for the next step, design work. In addition, it newly secured an order for an FS for a biopharmaceutical manufacturing facility.」
In the pharmaceutical and biochemical fields, the company advanced from completing the biopharmaceutical FS to securing an order for design work, and also newly secured an order for an FS for a biopharmaceutical manufacturing facility. - FY2025-H1AdvancedAnnual report
「The company newly secured an order for an FS for a biopharmaceutical manufacturing facility.」
In the pharmaceutical and biochemical fields, the company newly secured an order for an FS for a biopharmaceutical manufacturing facility. - FY2024AdvancedAnnual report
「In introducing and implementing continuous production technology developed in the petroleum field into the pharmaceutical field, the company newly secured orders for basic planning and basic design work for equipment.」
In the pharmaceutical and biochemical fields, the company newly secured orders for basic planning and basic design work for equipment to introduce and implement continuous production technology. - FY2024-Q3AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company newly secured an order from AGC㈱ for EPC work on a biopharmaceutical API manufacturing facility. It is also carrying out EPC work on several biopharmaceutical API manufacturing facilities and pharmaceutical manufacturing facilities for pharmaceutical companies.」
In the pharmaceutical and biochemical fields, the company newly secured an order from AGC㈱ for EPC work on a biopharmaceutical API manufacturing facility and advanced to the execution stage for multiple projects. - FY2023AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company completed the expansion of vaccine API manufacturing facilities using recombinant proteins and related facilities under a project for Shionogi & Co.,Ltd. It is also carrying out EPC work for biopharmaceutical API manufacturing facilities for other pharmaceutical companies and newly secured an order for the construction of a pharmaceutical API manufacturing facility.」
The company completed the expansion of vaccine API manufacturing facilities and related facilities, continued EPC work for biopharmaceutical API facilities, and advanced to securing a new order for a pharmaceutical API facility. - FY2023-Q3RestatedAnnual report
「Outside its EPC business, the joint venture Pharmira㈱, established by シオノギファーマ㈱ with the company as a participant, began operations in April 2022. It provides full-range, one-stop manufacturing of pharmaceutical APIs and intermediates, from process development and clinical-trial API production through commercial production. The company is responsible for implementing innovative continuous production technology and plans to strengthen its life sciences business through the broader deployment of this technology.」
The company reaffirmed its policy of strengthening the life sciences business through Pharmira㈱'s start of operations and the implementation and broader deployment of continuous production technology. - FY2023-Q2RestatedAnnual report
「Outside its EPC business, the joint venture Pharmira㈱, established by シオノギファーマ㈱ with the company as a participant, began operations in April of this year. It provides full-range, one-stop manufacturing of pharmaceutical APIs and intermediates, from process development and clinical-trial API production through commercial production. The company is responsible for implementing innovative continuous production technology and plans to strengthen its life sciences business through the broader deployment of this technology.」
The company reaffirmed Pharmira㈱'s start of operations and its role in implementing and broadly deploying continuous production technology. - FY2023-Q1AdvancedAnnual report
「Outside its EPC business, the joint venture Pharmira㈱, established by シオノギファーマ㈱ with the company as a participant, began operations on 1 April of this year. The company provides contract development and manufacturing services using continuous production technology for pharmaceutical APIs and intermediates, with the aim of implementing its continuous-flow synthesis technology.」
In the pharmaceutical and biochemical fields, the joint venture Pharmira㈱ began operations on 1 April, advancing to contract services from development through commercial production and the broader deployment of its technology. - FY2022-Q3AdvancedAnnual report
「Outside its EPC business, the company decided to participate in a joint venture to be established primarily by シオノギファーマ㈱. The joint venture will provide contract development and manufacturing services using continuous production technology for pharmaceutical APIs and intermediates, with the aim of implementing the company's continuous-flow synthesis technology.」
In the pharmaceutical and biochemical fields, the company decided to participate in a joint venture for contract development and manufacturing services aimed at implementing continuous-flow synthesis technology. - FY2022-Q2AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company is carrying out EPC work for the expansion of vaccine API manufacturing facilities using recombinant proteins and related facilities for Shionogi & Co.,Ltd. Basic design work for the biopharmaceutical API manufacturing plant was completed, and EPC work began.」
EPC work for the expansion of the vaccine API facilities continues, while the biopharmaceutical API manufacturing plant advanced from completion of basic design to the start of EPC work. - FY2022-Q1AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company is carrying out EPC work for the expansion of vaccine API manufacturing facilities using recombinant proteins and related facilities for Shionogi & Co.,Ltd. Basic design work for the biopharmaceutical API manufacturing plant was completed.」
The company is carrying out EPC work for the expansion of vaccine API manufacturing facilities and related facilities, while basic design work for the biopharmaceutical API manufacturing plant was completed. - FY2021-Q3AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company secured and is carrying out EPC work from Shionogi & Co.,Ltd. for a vaccine API manufacturing plant using recombinant proteins. It also secured and is carrying out basic design work for a biopharmaceutical API manufacturing plant. The pharmaceutical synthetic API manufacturing facility for which EPC work had been under way was completed.」
In the pharmaceutical and biochemical fields, the company newly secured and is carrying out EPC work for a vaccine API manufacturing plant and basic design work for a biopharmaceutical API manufacturing plant, and completed the pharmaceutical synthetic API manufacturing facility. - FY2021-Q2AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company is carrying out EPC work for pharmaceutical synthetic API manufacturing facilities and other projects. Outside its EPC business, it agreed with シオノギファーマ㈱ to jointly develop and study continuous production technology for pharmaceutical APIs and intermediates.」
In addition to EPC work for pharmaceutical manufacturing facilities, the company advanced to an agreement with シオノギファーマ㈱ to jointly develop and study continuous production technology for pharmaceutical APIs and intermediates. - FY2020-Q3AdvancedAnnual report
「In the pharmaceutical and biochemical fields, the company completed an intermediate-molecule pharmaceutical API manufacturing facility and is carrying out EPC work for pharmaceutical synthetic API manufacturing facilities and other projects.」
In the pharmaceutical and biochemical fields, the intermediate-molecule pharmaceutical API manufacturing facility advanced from being under construction to completion, while EPC work for pharmaceutical synthetic API manufacturing facilities and other projects continues. - FY2020-Q1RestatedAnnual report
「In Japan's pharmaceutical and biochemical fields, the company is carrying out EPC work for intermediate-molecule pharmaceutical API manufacturing facilities, pharmaceutical synthetic API manufacturing facilities and other projects.」
The company continues to carry out EPC work for intermediate-molecule pharmaceutical API manufacturing facilities, pharmaceutical synthetic API manufacturing facilities and other projects. - FY2019-Q3AdvancedAnnual report
「In Japan's pharmaceutical and biochemical fields, the company completed state-of-the-art injectable drug manufacturing facilities designed to handle highly potent active pharmaceutical ingredients and manufacturing facilities for separation and purification agents used in pharmaceutical production, while carrying out EPC work for intermediate-molecule pharmaceutical API manufacturing facilities, pharmaceutical synthetic API manufacturing facilities and other projects.」
In the pharmaceutical and biochemical fields, the company completed injectable drug manufacturing facilities and separation and purification agent manufacturing facilities, and continues to carry out EPC work for API-related facilities. - FY2019-Q2AdvancedAnnual report
「In Japan's pharmaceutical and biochemical fields, the company newly secured an order for EPC work on a pharmaceutical synthetic API manufacturing facility. It also completed a state-of-the-art injectable drug manufacturing facility designed to handle highly potent active pharmaceutical ingredients and a manufacturing facility for separation and purification agents used in pharmaceutical production, while carrying out EPC work for intermediate-molecule pharmaceutical API manufacturing facilities and other projects.」
In the pharmaceutical and biochemical fields, the company newly secured an order for a pharmaceutical synthetic API manufacturing facility and also reported the completion of an injectable drug manufacturing facility and other projects. - FY2019-Q1AdvancedAnnual report
「In Japan's pharmaceutical and biochemical fields, the company completed a state-of-the-art injectable drug manufacturing facility designed to handle highly potent active pharmaceutical ingredients and is carrying out EPC work for intermediate-molecule pharmaceutical API manufacturing facilities and other projects.」
In the pharmaceutical and biochemical fields, the company completed an injectable drug manufacturing facility designed to handle highly potent active pharmaceutical ingredients and continues to carry out EPC work for intermediate-molecule pharmaceutical API manufacturing facilities. - FY2018AdvancedAnnual report
「In Japan, the company is carrying out EPC work for flue-gas desulfurization facilities for coal-fired power plants, CO2 separation and capture demonstration facilities, and solar power facilities (mega-solar projects). In other fields, including food, pharmaceuticals and biochemistry, it completed a biopharmaceutical manufacturing facility in March 2018 and is carrying out EPC work for food plants and laboratories that comply with the latest food safety and hygiene standards, as well as state-of-the-art injectable drug manufacturing facilities and intermediate-molecule pharmaceutical API manufacturing facilities designed to handle highly potent active pharmaceutical ingredients.」
In the food and pharmaceutical fields, the company completed a biopharmaceutical manufacturing facility and continues to pursue projects involving food plants and laboratories, injectable drug manufacturing facilities and intermediate-molecule pharmaceutical API facilities. - FY2018-Q3RestatedAnnual report
「In other fields, including food, pharmaceuticals and biochemistry, the company is also carrying out EPC work for food plants and laboratories that comply with the latest food safety and hygiene standards, as well as state-of-the-art injectable drug manufacturing facilities, intermediate-molecule pharmaceutical API manufacturing facilities and biopharmaceutical manufacturing facilities designed to handle highly potent active pharmaceutical ingredients.」
The company continues to carry out EPC work for food plants and laboratories, as well as injectable drug, intermediate-molecule pharmaceutical API and biopharmaceutical manufacturing facilities. - FY2018-Q2RestatedAnnual report
「In other fields, including food, pharmaceuticals and biochemistry, the company is also carrying out EPC work for food plants and laboratories that comply with the latest food safety and hygiene standards, as well as state-of-the-art injectable drug manufacturing facilities, API manufacturing plants and biopharmaceutical manufacturing facilities designed to handle highly potent active pharmaceutical ingredients and antibody drugs.」
The company continues to carry out EPC work for food plants and laboratories, as well as injectable drug, API and biopharmaceutical manufacturing facilities. - FY2018-Q1RestatedAnnual report
「In other fields, including food, pharmaceuticals and biochemistry, the company is also carrying out EPC work for food plants and laboratories that comply with the latest food safety and hygiene standards, as well as state-of-the-art injectable drug manufacturing facilities, API manufacturing plants and biopharmaceutical manufacturing facilities designed to handle highly potent active pharmaceutical ingredients and antibody drugs.」
The company continues to carry out EPC work for food plants and laboratories, as well as injectable drug, API and biopharmaceutical manufacturing facilities. - FY2017AdvancedAnnual report
「In new fields, the company secured orders in environmental fields, including biojet fuel production, and in the life sciences field, including regenerative medicine facilities.」
The company states that, in addition to its existing food and pharmaceutical facilities businesses, it secured orders for environmental projects and regenerative medicine facilities. - FY2017-Q3RestatedAnnual report
「The company is also carrying out EPC work for food plants that comply with the latest food safety and hygiene standards. In the pharmaceutical field, it is carrying out EPC work for state-of-the-art injectable drug manufacturing facilities, active pharmaceutical ingredient (API) manufacturing plants, vaccine manufacturing plants and biopharmaceutical manufacturing facilities designed to handle highly potent active pharmaceutical ingredients and antibody drugs.」
The company continues to carry out EPC work for food plants that comply with food safety standards, as well as facilities related to injectable drugs, APIs and biopharmaceuticals. - FY2017-Q2RestatedAnnual report
「The company is also carrying out EPC work for food plants that comply with the latest food safety and hygiene standards. In the pharmaceutical field, it is carrying out EPC work for state-of-the-art injectable drug manufacturing facilities, active pharmaceutical ingredient (API) manufacturing plants, vaccine manufacturing plants and biopharmaceutical manufacturing facilities designed to handle highly potent active pharmaceutical ingredients and antibody drugs.」
The company continues to carry out EPC work for food plants that comply with food safety standards, as well as facilities related to injectable drugs, APIs, biopharmaceuticals and vaccines. - FY2017-Q1First statedAnnual report
「The company is also carrying out EPC work for food plants that comply with the latest food safety and hygiene standards. In the pharmaceutical field, it is carrying out EPC work for state-of-the-art injectable drug manufacturing facilities, active pharmaceutical ingredient (API) manufacturing plants, vaccine manufacturing plants and biopharmaceutical manufacturing facilities designed to handle highly potent active pharmaceutical ingredients and antibody drugs.」
The company is carrying out EPC work for facilities that comply with food safety standards and facilities for highly potent active pharmaceutical ingredients, antibody drugs, vaccines and biopharmaceuticals.